AstraZeneca and Merck hope new data can PROpel their PARP inhibitor into first-line prostate cancer – Endpoints News
Final yr, Clovis’ PARP inhibitor Rubraca beat AstraZeneca and Merck’s blockbuster Lynparza throughout the finish line in prostate cancer by ...
